Meropenem for injection

Meropenem binds to penicillin-binding proteins (PBPs) involved in cell wall synthesis through its covalent bond, thereby inhibiting the synthesis of bacterial cell walls and exerting an antibacterial effect. Meropenem is sensitive to both Gram-positive and Gram-negative bacteria, and has particularly strong antibacterial activity against Gram-negative bacteria. The minimum inhibitory concentration (MIC) for about 90% of Enterobacteriaceae is 0.08-0.15 mg/L; more than 90% of Pseudomonas aeruginosa strains are highly sensitive to it, with a minimum inhibitory concentration (MIC) of <4 mg/L; all Haemophilus (including ampicillin-resistant strains) are highly sensitive to it, with a minimum inhibitory concentration (MIC) of 0.06-1 mg/L; Neisseria gonorrhoeae are also highly sensitive to meropenem, and its activity is 15 times stronger than that of imipenem; Staphylococcus epidermidis, Staphylococcus saprophyticus and other

The main ingredient of this product is meropenem. Its chemical name is (-)-(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylaminoformyl)-3-pyrrolidinyl]sulfur}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylic acid trihydrate. [Molecular formula] C12H25N3O5S·3H2O [Molecular weight] 437.51

Meropenem binds to penicillin-binding proteins (PBPs) involved in cell wall synthesis through its covalent bond, thereby inhibiting the synthesis of bacterial cell walls and exerting an antibacterial effect. Meropenem is sensitive to both Gram-positive and Gram-negative bacteria, and has particularly strong antibacterial activity against Gram-negative bacteria. The minimum inhibitory concentration (MIC) for about 90% of Enterobacteriaceae is 0.08-0.15 mg/L; more than 90% of Pseudomonas aeruginosa strains are highly sensitive to it, with a minimum inhibitory concentration (MIC) of <4 mg/L; all Haemophilus (including ampicillin-resistant strains) are highly sensitive to it, with a minimum inhibitory concentration (MIC) of 0.06-1 mg/L; Neisseria gonorrhoeae are also highly sensitive to meropenem, and its activity is 15 times stronger than that of imipenem; Staphylococcus epidermidis, Staphylococcus saprophyticus and other

Meropenem is clinically applicable to the following infections caused by sensitive bacteria: 1. Respiratory system infections, such as chronic bronchitis, pneumonia, lung abscess, empyema, etc. 2. Intra-abdominal infections, such as cholecystitis, cholangitis, liver abscess, peritonitis, etc. 3. Urinary and reproductive system infections, such as pyelonephritis, complicated cystitis, adnexitis, intrauterine infection, pelvic inflammatory disease, uterine connective tissue inflammation, etc. 4. Bone, joint, skin and soft tissue infections, such as cellulitis, perianal abscess, osteomyelitis, arthritis, traumatic wound infection, burn wound infection, surgical incision infection, jaw and jaw cellulitis, etc. 5. Eye and ear, nose and throat infections. 6. Other serious infections, such as meningitis, sepsis, etc.

Intravenous administration: 1. For adults, conventional dose: 500-1000 mg every 8 hours. (1) Meningitis: 2000 mg every 8 hours. (2) Cancer patients with neutropenia and fever: 1000 mg every 8 hours. (3) Peritonitis caused by combined intra-abdominal infection and sensitive bacteria: 1000 mg every 8 hours. (4) Skin and soft tissue infection: 500 mg every 8 hours. (5) Urinary tract infection: 500 mg once, twice a day. 2. Dosage for renal insufficiency: For patients with creatinine clearance of 26-50 ml/min, 1000 mg every 12 hours; for patients with creatinine clearance of 10-25 ml/min, 500 mg every 12 hours; for patients with creatinine clearance of less than 10 ml/min, 500 mg every 24 hours. 3. Dosage for hepatic insufficiency: No dose adjustment is required for patients with mild hepatic insufficiency. 4. Dialysis dosage: It is recommended that dialysis patients increase the dosage during hemodialysis. 5. Pediatric dosage: 10-20 mg/kg per time, 3 times a day, based on body weight.

1. Allergic reactions: mainly rash, itching, drug fever and other allergic reactions; anaphylactic shock is occasionally seen. 2. Digestive system: mainly gastrointestinal symptoms such as diarrhea, nausea, vomiting, and constipation. 3. Liver: abnormal liver function, cholestatic jaundice, etc. are occasionally seen. 4. Kidney: dysuria and acute renal failure are occasionally seen. 5. Central nervous system: occasionally insomnia, anxiety, confusion, dizziness, nervousness, paresthesia, hallucinations, depression, convulsions, impaired consciousness and other central nervous system symptoms. There are reports abroad that epileptic seizures may be induced after medication. 6. Blood system: bleeding symptoms such as gastrointestinal bleeding, epistaxis and peritoneal hemorrhage are occasionally seen. 7. Injection may cause local pain, redness, swelling, and nodules, and in severe cases, thrombophlebitis.

It is contraindicated for those who are allergic to this product.

Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. Precautions for the elderly: The dosage should be reduced in the elderly due to the prolonged half-life.

1. The combined use of probenecid and this product can reduce the plasma clearance rate of this product and prolong its half-life. 2. The use of this product together with the live typhoid vaccine may interfere with the immune response of the live typhoid vaccine. 3. It has been reported that the combined use of anti-epileptic drugs and this product can reduce the plasma concentration of anti-epileptic drugs.

Store tightly closed in a cool, dark and dry place.

0.5g

PKU HealthCare Corp., Ltd.

• Founded in:

  1993-05-18

• Address:

  No. 21, Fangzheng Avenue, Shuitu Town, Beibei District, Chongqing

• Tax NO.:

  91500000450533779H

• Registered Funds:

  595.987425 yuan

• Website:

  Log in to view

• Email:

  Log in to view